MEDEOR THERAPEUTICS is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of personalized cellular immunotherapies to improve outcomes in organ transplant recipients. Our team of professionals possesses deep expertise in hematology, cellular immunotherapy, and transplantation product development. Medeor’s series of product candidates each comprise a unique composition of different types of hematopoietic organ donor-derived cells, based on breakthrough technologies discovered at Stanford University and exclusively licensed by Medeor. These product candidates are designed to produce mixed chimerism, the co-existence of both recipient and donor blood and immune cells in the recipient, to achieve donor-specific immune tolerance, to prevent transplant organ loss, to reduce or eliminate chronic immunosuppressive drug therapy, and thereby to improve patient outcomes. Our pipeline addresses critical medical needs of the approximately 130,000 annual organ transplant recipients worldwide, including greater than 30,000 annual transplant recipients in the US alone. Medeor is headquartered in San Mateo, California.